News | February 03, 2012

Colibri Heart Valve Issued Patent for New Method of Making Replacement Heart Valves

February 3, 2012 — Colibri Heart Valve received an notification it received patents for a new transcatheter heart valve from the United States Patent and Trademark Office.  The office sent noyice it is granting granting U.S. Patent No. 8,109,995 for "Percutaneously Implantable Replacement Heart Valve Device And Method Of Making Same." The patent will issue on Feb. 7, 2012 and is directed to a method of making a percutaneously implantable replacement transcatheter aortic heart valve using a folding technique covering both bovine and porcine pericardium. The associated patent application (12/228,192) has priority claims with content dating back to Jan. 4, 2002. It is expected that the patent will provide Colibri with broad protection to prevent others from producing or distributing valves based on this folding technique through Jan. 4, 2022.

"We believe that replacement heart valves that use the unique folded tissue design will have meaningful benefits over currently available valves, including a reduced profile and increased resistance to wear," said Joseph B. Horn, Colibri’s president and CEO. "With this IP in place, and with additional patents pending directed to a pre-packaged, sterilized, percutaneous heart valve delivered through a 14 French sheath, we believe Colibri is well positioned to initiate first-in-human clinical trials with the Colibri valve later this year."

Colibri recently completed a $5 million Series B financing by a consortium of angel and high net-worth private investors. This capital will be used to commence a first-in-human clinical trial of the Colibri valve replacement system in patients with a symptomatic stenotic aortic valve who are candidates for transcatheter aortic heart valve implantation (TAVI). This study will seek to enroll five to 10 patients in pre-identified centers in Western Europe.

About the Colibri Valve Replacement System for TAVI

TAVI has become an important treatment option in the United States for heart valve replacement due to its minimally invasive nature, clinical efficacy, extensive patient experience as an approved procedure in the United States and Europe, and reduced procedural costs. Colibri’s heart valve device incorporates advantages not in other available valves or those in known development. These advantages come through unique features including a significant profile reduction compared to other available devices, a folded valve construct using minimal sutures, thin and durable low-profile tissue leaflets, a dry valve which is pre-mounted at manufacture and pre-packaged with the valve fully integrated in its delivery system. The proprietary double balloon technology allows stabilized valve deployment and adjustment capabilities for accurate valve placement. Colibri’s proprietary tissue preparation process makes the Colibri replacement heart valve highly biocompatible and resistant to calcification.

For more information:

Related Content

Videos | Heart Valve Technology | March 15, 2018
Insights from the STS/ACC TVT Transcatheter Valve Registry, presented at the American College of Cardiology (ACC) 201
CoreValve TAVR System Shows Strong Long-Term Performance in Clinical Trials
News | Heart Valve Technology | March 12, 2018
Medtronic plc unveiled outcomes from the CoreValve U.S. Pivotal Extreme Risk Study and the real-world NOTION trial (...
The U.S. Food and Drug Administration expanded the approval of a heart valve to include a size small enough to be used in newborn pediatric patients to treat heart defects.
News | Heart Valve Technology | March 07, 2018
The U.S. Food and Drug Administration expanded the approval of a heart valve to include a size small enough to be used...
Videos | Heart Valve Technology | March 02, 2018
Sammy Elmariah, M.D., MPH, interventional structural heart disease, Massachusetts General Hospital, discusses the pro
Boston Scientific Projects 2019 Launch for Lotus Edge Aortic Valve System
News | Heart Valve Technology | February 23, 2018
February 23, 2018 — Boston Scientific announced In November 2017 a delay to timelines for commercialization of the Lo
Gate Bioprosthesis Used in Canada's First Transcatheter Valve Replacement for Tricuspid Regurgitation
News | Heart Valve Technology | February 22, 2018
NaviGate Cardiac Structures Inc. (NCSI)announced that on Feb. 2, 2018, its catheter-guided Gate valved-stent...
Edwards Lifesciences Centera self expanding transcatheter (TAVR) valve has been approved with CE mark for use in Europe.
Feature | Heart Valve Technology | February 15, 2018
February 15, 2018 — Edwards Lifesciences Corp.
Boston Scientific Enters Investment and Acquisition Option Agreement With Millipede
News | Heart Valve Technology | January 24, 2018
Boston Scientific Corp. announced it has closed an investment and entered into an acquisition option agreement with...
Edwards LifeSciences Recalls Sapien 3 Certitude Delivery System
News | Heart Valve Technology | January 11, 2018
The U.S. Food and Drug Administration (FDA) announced that Edwards LifeSciences is recalling its Certitude Delivery...
Videos | Heart Valve Technology | January 04, 2018
Adam Greenbaum, M.D., co-director, Center for Structural Heart Disease, Henry Ford Hospital, Detroit, explains how hi
Overlay Init